Before a vaccine against COVID-19 is available, it is still the health situation that drives the economy and financial markets. Once a vaccine becomes available, the analysis to be made is about irreversibilities, about what remains different despite the health situation returning to normal: changes in behaviour, acceleration of the energy transition and deterioration in the structure of corporate balance sheets, per Natixis.
More – Implementing national lockdowns to lead to a new bear market for stocks – Charles Schwab
Key quotes
“As long as there is neither a vaccine nor an effective treatment against COVID-19, the health situation will continue to play a leading role for the economy and financial markets. Given that the health situation is worsening again in the Americas, India and Europe, there is a risk of a further decline in activity at the end of 2020 and the beginning of 2021due to restrictive measures taken by governments, disruption in companies if there are many cases and a decline in household confidence. This decline in activity is already giving rise to a downturn in share prices.”
“Once a vaccine and an effective treatment against COVID-19 become available, is it possible to return to the same economic situation as before the crisis? The answer is no, since some aspects of the economy will be permanently different, since there will be irreversibilities.”
“We see three irreversibilities about what remains different despite the health situation returning to normal. Permanent changes in behaviour, for example, remote working, online consumption, a drop in business travel, leading to permanent weakness for office real estate, traditional retail and air transport. The COVID-19 crisis has triggered, without many scientific reasons, the desire to speed up the energy transition, and therefore an accelerated shift to electric cars, faster development of renewable energies and new technologies (hydrogen, carbon capture, etc.), and an effort to insulate buildings and housing. Corporate balance sheets are deteriorating in 2020, due to falling earnings and therefore a loss of equity and rising debt. Even a company that will return to normal revenues once a vaccine becomes available will suffer from the deterioration in its balance sheet structure, leading to a weakening of investment and employment.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD drops below 1.0800 after German Retail Sales data
EUR/USD has come under fresh selling pressure and trades below 1.0800 after the data from Germany showed that Retail Sales declined by 1.9% MoM in February. Resurgent US Dollar demand is adding to the downside in the pair. US data are next in focus.
GBP/USD stays weak near 1.2600 amid market caution
GBP/USD remains defensive near 1.2600 in European trading on Thursday. The hawkish tone from Fed Governor Christopher Waller keeps the US Dollar afloat amid a cautious trading environment ahead of key US data releases and the Good Friday trading lull.
Gold price bulls keenly await US PCE Price Index on Friday before placing fresh bets
Gold price (XAU/USD) continues with its struggle to make it through the $2,200 mark on Thursday and oscillates in a narrow trading band through the early part of the European session.
XRP price falls to $0.60 support as Ripple ruling doesn’t help Coinbase lawsuit against SEC
XRP programmatic sales ruling by Judge Torres was completely rejected by another US Court that ruled in favor of the SEC in a lawsuit against Coinbase.
Portfolio rebalancing and reflation trades emerge into Q2
Yesterday’s price action pointed at a possible end-of-quarter portfolio rebalancing as the session saw the laggards of the quarter like Apple and Tesla gain, and the stars like Microsoft and Nvidia retreat.